Benzinga | Jun 30, 2021 09:06AM EDT

B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $21

B. Riley Securities analyst Mayank Mamtani maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $41 to $21.